levamlodipine besylate

Also Known As:

3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4S)-, benzenesulfonate (1:1); 3-Ethyl 5-methyl (4S)-2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylate benzenesulfonate (1:1)

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dihydropyridines: 214
      - Amlodipine: 2808
        levamlodipine besylate: 4

Experts

1.	Dai, Guo-Yao: 1 article (04/2022)
2.	Zhu, Ye-Hua: 1 article (04/2022)
3.	Li, Chang-Xin: 1 article (08/2021)
4.	Wang, Ruo-Jun: 1 article (08/2021)
5.	Xu, Sui-Yi: 1 article (08/2021)
6.	Zhang, Lei: 1 article (08/2021)
7.	Gao, Yin-Ping: 1 article (12/2019)
8.	Han, Feng: 1 article (12/2019)
9.	Jiang, Guo-Jun: 1 article (12/2019)
10.	Liao, Mei-Hua: 1 article (12/2019)

Related Diseases

1.	Essential Hypertension 04/01/2022 - "The analysis will evaluate the efficiency and level of safeness of levamlodipine besylate combined treatment for essential hypertension. " 04/01/2022 - "The current study's aim is to investigate the effectiveness as well as safety of levamlodipine besylate combination therapy in treating essential hypertension at varying degrees of severity. " 04/01/2022 - "Our systematic review will offer evidence for judging whether levamlodipine besylate combination therapy can be considered an effective intercession for essential hypertension. " 04/01/2022 - "Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis." 04/01/2022 - "In establishing the effectiveness and safety of the mix of levamlodipine besylate and dihydropyridine for essential hypertension, the authors will conduct a systematic review and, where applicable, a meta-analysis of randomized controlled clinical trials. "
2.	Insulin Resistance 05/01/2016 - "The improvement of insulin resistance by losartan potassium at 12 months might be better than that by levamlodipine besylate; however, after 24 and 36 months of follow-up, both agents significantly alleviated insulin resistance. " 05/01/2016 - "The antihypertensive effect of losartan and levamlodipine besylate could amoliorate insulin resistance in patients with EH combined with i-IFG. " 05/01/2016 - "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG). " 05/01/2016 - "Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose."
3.	Cognitive Dysfunction 12/03/2019 - "Here, we reported that low-dose levamlodipine besylate could reverse the cognitive impairment in VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO). "
4.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 12/03/2019 - "Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia."
5.	Hypertension (High Blood Pressure) 08/20/2021 - "Fifteen years prior to this admission, he began taking levamlodipine besylate inconsistently for hypertension, but the level of blood pressure control was uncertain. "

Related Drugs and Biologics

1.	Losartan (Cozaar)
2.	Glucose (Dextrose)
3.	Antihypertensive Agents (Antihypertensives)
4.	1,4-dihydropyridine (dihydropyridine)

Related Therapies and Procedures

1.	Therapeutics